In combined studies , serious adverse events were reported in @ ( @ % ) of @ patients given ixekizumab every @ weeks , @ ( @ % ) of @ given ixekizumab every @ weeks , seven ( @ % ) of @ given placebo , and @ ( @ % ) of @ given etanercept ; no deaths were noted .